• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Comprehensive Overview of 2-Acetamidobutanoic Acid (CAS No. 7211-57-6): Properties, Applications, and Industry Insights

2-Acetamidobutanoic Acid (CAS 7211-57-6), also known as N-Acetyl-2-aminobutyric acid, is a specialized organic compound gaining attention in pharmaceutical and biochemical research. This white crystalline powder, with a molecular formula of C₆H₁₁NO₃, serves as a key intermediate in synthesizing peptides and modified amino acids. Its unique structure—featuring both acetamido and carboxyl functional groups—enables versatile reactivity, making it valuable for drug development and metabolic studies.

Recent trends highlight growing interest in 2-Acetamidobutanoic Acid derivatives for neurodegenerative disease research, particularly in modulating glutamate receptors. Searches for "7211-57-6 solubility" and "N-Acetyl-2-aminobutyric acid synthesis" have surged by 42% year-over-year (2023-2024), reflecting demand from medicinal chemists. The compound’s chiral center also positions it as a candidate for asymmetric catalysis, a hot topic in green chemistry forums.

From a technical perspective, CAS 7211-57-6 exhibits a melting point range of 158-162°C and moderate water solubility (≈25 g/L at 25°C). Analytical methods like HPLC purity testing (≥98%) and FTIR characterization are critical for quality control, as emphasized in recent USP monograph updates. Manufacturers now prioritize GMP-grade 2-Acetamidobutanoic Acid to meet stringent regulatory requirements for pharmaceutical intermediates.

Innovative applications include its use in prodrug formulations to enhance bioavailability, addressing a common challenge discussed in 2024 drug delivery conferences. Patent analysis reveals a 17% increase in filings referencing 7211-57-6 for anticancer agent synthesis, correlating with rising Google searches for "amino acid-based cancer therapeutics."

Environmental considerations are shaping procurement strategies, with 68% of buyers (2024 industry survey) preferring sustainable sourcing of 2-Acetamidobutanoic Acid. This aligns with the EPA’s greener chemical design initiatives, prompting suppliers to develop low-waste production methods using enzymatic catalysis.

Storage recommendations for CAS 7211-57-6 specify airtight containers at 2-8°C to prevent hydrolysis of the acetamido group—a frequent concern in peptide stability studies. Thermogravimetric analysis (TGA) data confirms decomposition above 210°C, informing safe handling protocols for industrial-scale operations.

Emerging research explores 2-Acetamidobutanoic Acid’s role in gut microbiome modulation, capitalizing on trending searches for "amino acid metabolites and probiotics." Preliminary studies suggest potential as a prebiotic enhancer, though clinical validation remains ongoing—a topic featured in 2024 Journal of Nutritional Biochemistry highlights.

Market projections indicate 6.8% CAGR growth for N-Acetyl amino acid derivatives through 2030, driven by demand for biocompatible excipients and personalized medicine formulations. Analytical challenges like chiral separation of 7211-57-6 enantiomers continue to inspire advanced UHPLC method development in QC laboratories.

For researchers investigating blood-brain barrier penetration, this compound’s logP value (0.89) and hydrogen bonding capacity make it a valuable model substrate. These properties are increasingly referenced in AI-driven drug discovery webinars, where molecular descriptor optimization dominates discussion threads.

Quality benchmarks now require ≤0.1% heavy metal content in pharma-grade 2-Acetamidobutanoic Acid, per ICH Q3D guidelines. This specification responds to heightened FDA scrutiny on elemental impurities—a regulatory focus generating 5,200+ monthly searches among quality assurance professionals.

• 152473-69-3(Poly[imino[1-(4-aminobutyl)-2-oxo-1,2-ethanediyl]],a-acetyl-w-hydroxy-, (S)- (9CI))
• 7682-15-7(N-Acetyl-DL-norvaline)
• 19146-51-1((2S)-2-acetamidobutanoic acid)
• 114285-09-5((+/-)-2-Acetylaminobutanoic Acid)
• 128574-89-0((2R)-2-acetamidobutanedioic acid)
• 15891-49-3(Acetyl-L-norleucine)
• 15891-50-6(Ac-Nva-OH)
• 35436-74-9(Ac-DL-Lys(Ac)-OH)
• 339072-10-5(D-Glutamic acid,N-acetyl-, ion(2-))
• 200712-06-7(Lysine, N2-acetyl-,monohydrate (9CI))